Title |
Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study
|
---|---|
Published in |
Diabetes Care, January 2012
|
DOI | 10.2337/dc11-1109 |
Pubmed ID | |
Authors |
Ru-Dee Ting, Anthony C. Keech, Paul L. Drury, Mark W. Donoghoe, John Hedley, Alicia J. Jenkins, Timothy M.E. Davis, Seppo Lehto, David Celermajer, R. John Simes, Kushwin Rajamani, Kim Stanton |
Abstract |
Diabetic patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30-59 mL/min/1.73 m(2)) are at particular cardiovascular risk. Fenofibrate's safety in these patients is an issue because it may elevate plasma creatinine. Furthermore, guidelines regarding fenofibrate dosing in renal impairment vary internationally. We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 25% |
Australia | 1 | 13% |
Unknown | 5 | 63% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 88% |
Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
South Africa | 1 | <1% |
Canada | 1 | <1% |
Denmark | 1 | <1% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 138 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 21 | 15% |
Student > Master | 17 | 12% |
Student > Ph. D. Student | 13 | 9% |
Researcher | 11 | 8% |
Student > Postgraduate | 9 | 6% |
Other | 29 | 20% |
Unknown | 43 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 28% |
Nursing and Health Professions | 17 | 12% |
Agricultural and Biological Sciences | 10 | 7% |
Biochemistry, Genetics and Molecular Biology | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Other | 19 | 13% |
Unknown | 49 | 34% |